Analisi facoltativa del prodotto
Con il tuo consenso utilizziamo analisi limitate e rispettose della privacy per capire quali percorsi di ricerca funzionano. Non usiamo tracker pubblicitari né registrazioni delle sessioni. Puoi modificare questa scelta nelle Preferenze. Leggi la Informativa sulla privacy.
Kimberly-Clark Corporation's published Buy conclusion compares the analysis-date price with fair value and potential value. Read the full report for assumptions, evidence, and material risks.
| Market cap | $31.3B | |
|---|---|---|
| P/E (forward) | 13.1x |
Recent price action with selectable time range.
| Item | P1 | P2 | P3 | P4 | P5 | Trend |
|---|---|---|---|---|---|---|
| Period | 2021-12-31 | 2022-12-31 | 2023-12-31 | 2024-12-31 | 2025-12-31 | Trend |
| Revenue | $19.44B | $20.18B | $17.15B | $16.81B | $16.45B | -4.1% |
| Gross profit | $5.99B | $6.22B | $6.27B | $6.29B | $5.92B | -0.3% |
| Operating income | $2.56B | $2.68B | $1.93B | $2.70B | $2.35B | -2.1% |
| Net income | $1.81B | $1.93B | $1.76B | $2.55B | $2.02B | +2.7% |
| EPS (diluted) | $5.35 | $5.72 | $5.21 | $7.55 | $6.07 | +3.2% |
| EBITDA | $3.25B | $3.38B | $2.34B | $3.98B | $3.11B | -1.1% |
| R&D | $269.0M | $292.0M | $303.0M | $328.0M | $326.0M | +4.9% |
| SG&A | $3.40B | $3.58B | $3.88B | $4.31B | $3.53B | +0.9% |
Recent company headlines from major financial publishers.
In the base case, Kimberly-Clark delivers steady turnaround execution, with revenue expanding 0.96% in FY2026 ($16,605M) and 2.65% in FY2027 ($17,045M). Operating margins widen through FY2030 as the 2024 Transformation Initiative offsets input inflation and normalizes supply chain operations, supporting Fair value at $121.76.
In the bull case, premium innovation tiering accelerates volume-plus-mix expansion across Huggies, Kleenex, and Kotex, while the resolution of false China quality allegations drives a sharper recovery in International Personal Care. Gross productivity savings exceed baseline cost inflation, expanding operating margins toward peer benchmarks and generating robust free cash flow to accelerate debt reduction and shareholder returns, supporting valuation toward $163.21.
| Ke ↓ / g → | 1.5% | 1.8% | 2.0% | 2.3% | 2.5% |
|---|---|---|---|---|---|
| 5.7% | $135 | $141 | $147 | $154 | $163 |
| 6.2% | $124 | $128 | $133 | $138 | $145 |
| 6.7% | $115 | $118 | $122 | $126 | $131 |
| 7.2% | $107 | $110 | $113 | $116 | $120 |
| 7.7% | $101 | $103 | $105 | $108 | $111 |
Upcoming earnings date and setup when available.
Il rating riportato dall'edizione di ricerca pubblicata ogni mese. Un rating confronta il prezzo alla data dell'analisi con il valore equo; non indica se la valutazione si è rivelata corretta.
| Anno | gen | feb | mar | apr | mag | giu | lug | ago | set | ott | nov | dic |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026 |